Trending...
- Bringing AI Innovations to the Job Site, Shly and LATO AI Boost Client Satisfaction
- The New Evangelicals Announces New Executive Director and Expanded Leadership Team
- 123Invent Inventor Develops Device to Protect Against Gunfire (CTK-1678)
PHILADELPHIA, July 29, 2025 /PRNewswire/ -- Berger Montague PC, a Philadelphia-based law firm focused on investor protection, is investigating claims against Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) ("Rocket Pharmaceuticals" or the "Company") for potential violations of federal securities laws. A class action has been filed over allegations that the Company concealed safety concerns tied to its RP-A501 trial, leading to steep investor losses.
Rocket Pharmaceuticals is headquartered in Cranbury, New Jersey, where it operates its research and clinical programs in genetic medicine.
According to the complaint, the Company introduced a new immunomodulatory agent into the RP-A501 protocol, information that was not disclosed to shareholders before a patient suffered a fatal adverse event. The Company later announced an FDA clinical hold, triggering a nearly 37% stock price decline over two trading days.
More on The PennZone
Individuals who purchased Rocket Pharmaceuticals securities during the Class Period from September 17, 2024 through May 26, 2025, may be eligible to join the class action. The deadline to file for lead plaintiff is August 11, 2025. To learn more about your rights, CLICK HERE.
About Berger Montague
Berger Montague is headquartered in Philadelphia and has offices in Chicago; Malvern, PA; Minneapolis; San Diego; San Francisco; Toronto, Canada; Washington, D.C., and Wilmington, DE. The Firm has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.
For more information or to discuss your rights, please contact:
Andrew Abramowitz, Senior Counsel
Berger Montague
(215) 875-3015
[email protected]
Caitlin Adorni
Berger Montague
(267) 764-4865
[email protected]
SOURCE Berger Montague
Rocket Pharmaceuticals is headquartered in Cranbury, New Jersey, where it operates its research and clinical programs in genetic medicine.
According to the complaint, the Company introduced a new immunomodulatory agent into the RP-A501 protocol, information that was not disclosed to shareholders before a patient suffered a fatal adverse event. The Company later announced an FDA clinical hold, triggering a nearly 37% stock price decline over two trading days.
More on The PennZone
- AdvoCast Expands Leadership in Strategic Comms with New Role Producing "Communication Breakdown" Podcast
- Rocket.Chat assessed "Awardable" for Department of Defense work in the CDAO's Tradewinds Solutions Marketplace
- David L. Lawrence Convention Center Selects showNets for 3-Year Internet & Wi-Fi Network Management Partnership
- Success for Global Communications Leader IQSTEL, Inc. Growing From $13 Million Revenue in 2018 to Nearly $300 Million Last Year
- YPTC Wins #1 Best Place to Work in Philadelphia
Individuals who purchased Rocket Pharmaceuticals securities during the Class Period from September 17, 2024 through May 26, 2025, may be eligible to join the class action. The deadline to file for lead plaintiff is August 11, 2025. To learn more about your rights, CLICK HERE.
About Berger Montague
Berger Montague is headquartered in Philadelphia and has offices in Chicago; Malvern, PA; Minneapolis; San Diego; San Francisco; Toronto, Canada; Washington, D.C., and Wilmington, DE. The Firm has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.
For more information or to discuss your rights, please contact:
Andrew Abramowitz, Senior Counsel
Berger Montague
(215) 875-3015
[email protected]
Caitlin Adorni
Berger Montague
(267) 764-4865
[email protected]
SOURCE Berger Montague
Filed Under: Business
0 Comments
Latest on The PennZone
- Conservative Latinos for PA Shaping the Future of Hispanic Community, Guest State Treasurer Stacy Garrity
- Chasing Creative Plants Roots in Palm Coast, Builds Marketing Systems for Modern B2B Brands
- Shane Victorino & Together We Dance Foundation Host Special Needs Families at Phillies Game
- David M. White, DDS Celebrates 500 Five-Star Reviews in Reno
- Medical Guardian Offers Mom's Meals® Benefit to Help Members Recover at Home and Prevent Hospital Readmission
- BJ Simmons Releases Trapped In
- Authentise and Kform Launch DDNA, Unveiling New Model for Defense Innovation
- Shincheonji Reaches World-Class Level At International Taekwondo Competition
- Retirement Expert Michael Seibert Joins Tom Hegna on "Financial Freedom with Tom Hegna"
- TNT Removal & Disposal Celebrates Record Year Helping Pennsylvania Property Owners Reclaim Space
- SpaceWERX selects New Frontier Aerospace to Develop Bifröst Orbit Transfer Spacecraft
- Postmortem Pathology Offers Expert Autopsy Services with Dignity and Accuracy
- Private Autopsies Provide Families in Colorado with Answers and Closure
- Vijay Tirathrai named Managing Director in Dubai, UAE
- Meet &insurance: The New Amenity Platform
- How smart women use BAY Miner cloud mining to easily earn Bitcoin every day
- Qualis LLC Appoints Jeremy Mallicoat as Chief Financial Officer to Advance Growth and Acquisition Strategy
- DATA BREACH ALERT: Edelson Lechtzin LLP is Investigating Claims on Behalf of Allianz Life Insurance Company of North America Customers Whose Data May Have Been Compromised
- Bynn Intelligence Reinvents Document Fraud Detection with Groundbreaking Acquisition and Revolutionary AI Model
- 2A Commerce Launches Firearms eCommerce Platform